LibtayoReceives Health Canada Approval for Adjuvant Treatment Of High-Risk Cutaneous Squamous Cell Carcinoma
https://www.newswire.ca/news-releases/libtayo-r-cemiplimab-for-injection-receives-health-canada-approval-for-adjuvant-treatment-of-high-risk-cutaneous-squamous-cell-carcinoma-809797655.html
Libtayo, a cancer medicine made by Regeneron, got official approval in Canada to help prevent a serious skin cancer from coming back after surgery. This is good news because it means more patients can use the medicine, which could help the company earn more money.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.